|
|
| MRI measures and their relations with clinical disability in relapsing-remitting and secondary progressive Multiple Sclerosis |
221 |
| E Giugni,
C Pozzilli,
S Bastianello,
C Gasperini,
A Paolillo,
T Koudriavtseva,
M Frontoni,
D Farina & L Bozzao
|
|
Abstract
Full Article (PDF)
|
|
| Inter-rater variability in reporting enhancing lesions present on standard and triple dose gadolinium scans of patients with multiple sclerosis |
226 |
| M Filippi,
F Barkhof,
S Bressi,
TA Yousry & DH Miller
|
|
Abstract
Full Article (PDF)
|
|
| 1H MRSI of normal appearing white matter in multiple sclerosis |
231 |
| WD Rooney,
DE Goodkin,
N Schuff,
DJ Meyerhoff,
D Norman & MW Weiner
|
|
Abstract
Full Article (PDF)
|
|
| T cell-T cell activation in multiple sclerosis |
238 |
| JW Lindsey,
RH Kerman & JS Wolinsky
|
|
Abstract
Full Article (PDF)
|
|
| Influenza virus vaccination of patients with multiple sclerosis |
243 |
| Foroozan Mokhtarian,
Djamshid Shirazian,
Linda Morgante,
Aaron Miller,
David Grob & Edgar Lichstein
|
|
Abstract
Full Article (PDF)
|
|
| Treatment of multiple sclerosis with high-dose corticosteroids may prolong the prothrombin time to dangerous levels in patients taking warfarin |
248 |
| Michael Kaufman
|
|
Abstract
Full Article (PDF)
|
|
| Open label gabapentin treatment for pain in multiple sclerosis |
250 |
| Maria K Houtchens,
John R Richert,
Arif Sami & John W Rose
|
|
Abstract
Full Article (PDF)
|
|
| Depression, coping and level of neurological impairment in multiple sclerosis |
254 |
| David C Mohr,
Donald E Goodkin,
Nicole Gatto & Judy Van Der Wende
|
|
Abstract
Full Article (PDF)
|
|
| Lay Summaries of Papers (3.4) |
259 |
| J Kirk
|
|
Abstract
Full Article (PDF)
|
|